as 02-21-2025 4:00pm EST
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
Founded: | 1986 | Country: | United States |
Employees: | N/A | City: | CRANBURY |
Market Cap: | 25.4M | IPO Year: | 1993 |
Target Price: | $7.00 | AVG Volume (30 days): | 1.7M |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.48 | EPS Growth: | N/A |
52 Week Low/High: | $0.68 - $3.99 | Next Earning Date: | 02-13-2025 |
Revenue: | $350,000 | Revenue Growth: | -95.07% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
PTN Breaking Stock News: Dive into PTN Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
9 days ago
GuruFocus.com
9 days ago
PR Newswire
9 days ago
PR Newswire
12 days ago
PR Newswire
15 days ago
Clinical Trials Arena
15 days ago
PR Newswire
16 days ago
PR Newswire
25 days ago
The information presented on this page, "PTN Palatin Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.